

# **Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/CD955820DAEEN.html>

Date: February 2018

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: CD955820DAEEN

## **Abstracts**

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018

### **SUMMARY**

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Caspase 9 - Pipeline Review, H1 2018, outlays comprehensive information on the Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Caspase-9 is an initiator caspase encoded by the CASP9 gene. Binding of caspase-9 to Apaf-1 leads to activation of the protease which cleaves and activates caspase-3. It is involved in the activation cascade of caspases responsible for apoptosis execution. It promotes DNA damage-induced apoptosis in an ABL1/c-Abl-dependent manner. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages

comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Metabolic Disorders, Ophthalmology and Toxicology which include indications Age Related Macular Degeneration, Autoimmune Hepatitis, Bladder Cancer, Breast Cancer, Chemotherapy Induced Neutropenia, Colorectal Cancer, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatitis C, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Metastatic Brain Tumor, Multiple Myeloma (Kahler Disease), Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Portal Hypertension, Prostate Cancer, Renal Failure, Small-Cell Lung Cancer, Solid Tumor and Urinary Tract Cancer.

Furthermore, this report also reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)

The report reviews Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics and enlists all their major and minor projects

The report assesses Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Overview

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Companies Involved in

Therapeutics Development

Bellicum Pharmaceuticals Inc

BeyondSpring Pharmaceuticals Inc

Novartis AG

Pharmedartis GmbH

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Drug Profiles

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flavokawain A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBRI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related  
Macular Degeneration and Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rimiducid + rivoignecleucel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Caspase 8, 9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE  
Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Dormant Products

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE  
Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Discontinued Products

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE  
Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Product Development

Milestones

Featured News & Press Releases

Feb 05, 2018: BeyondSpring Summarizes Key Messages from KOL Call regarding Lead  
Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

Jan 30, 2018: Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical  
Trials in the United States

Jan 26, 2018: BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018  
ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 17, 2018: BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase  
2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced  
Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Dec 14, 2017: BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3

Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

Dec 07, 2017: BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017

Dec 04, 2017: BeyondSpring's Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

Nov 30, 2017: BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority

Oct 26, 2017: BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

Oct 23, 2017: BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline

Oct 18, 2017: BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco

Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

Jul 06, 2017: China FDA Approves CTAs for BeyondSpring's Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention

Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

Jun 15, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indications, H1 2018  
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Bellicum Pharmaceuticals Inc, H1 2018  
Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018  
Pipeline by Novartis AG, H1 2018  
Pipeline by Pharmedartis GmbH, H1 2018  
Dormant Products, H1 2018  
Dormant Products, H1 2018 (Contd.1), H1 2018  
Discontinued Products, H1 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Bellicum Pharmaceuticals Inc

BeyondSpring Pharmaceuticals Inc

Novartis AG

Pharmedartis GmbH

## I would like to order

Product name: Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/CD955820DAEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD955820DAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

